Cargando…

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study

The treatment of advanced triple-negative breast cancer, which failed in first-line or second-line therapy, is a significant challenge. We conducted this retrospective study to explore the efficacy and safety of apatinib and capecitabine as the third-line treatment for advanced triple-negative breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yi-Hui, Zhou, Yang, Wang, Yu-Wei, Tong, Ling, Jiang, Run-Xue, Xiao, Lei, Zhang, Guang-Ju, Xing, Shu-Shan, Qian, Fang, Feng, Jing-Qi, Zhao, Ya-Ling, Wang, Jian-Gong, Wang, Xiao-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133618/ https://www.ncbi.nlm.nih.gov/pubmed/30200142 http://dx.doi.org/10.1097/MD.0000000000012222

Ejemplares similares

Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer
por: Miger, Jasmine, et al.
Publicado: (2014)

Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)
por: Noorali, Sima, et al.
Publicado: (2021)

A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer
por: Vasey, P A, et al.
Publicado: (2003)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

The role of Xeloda in metastasic breast cancer
por: Cortés-Funes, H
Publicado: (2005)

In vitro anti-proliferative effect of capecitabine (Xeloda) combined with mocetinostat (MGCD0103) in 4T1 breast cancer cell line by immunoblotting
por: Kaya Çakir, Hacer, et al.
Publicado: (2021)

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
por: Delord, J P, et al.
Publicado: (2005)

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
por: Talbot, D C, et al.
Publicado: (2002)

Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy Reduced Cervical Lymphadenopathy and Dermal Involvement in Patient With Recurrent Breast Cancer: Case Report
por: Saure Sarría, Victor Manuel, et al.
Publicado: (2020)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis
por: Wang, Yan, et al.
Publicado: (2014)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Capecitabine-induced Leukoencephalopathy
por: Yoshimura, Kenji, et al.
Publicado: (2018)

Capecitabine-Induced Enterocolitis
por: Khan, Muzammil, et al.
Publicado: (2022)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
por: Tang, Lin-Quan, et al.
Publicado: (2023)

Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
por: Xu, Ju Ling, et al.
Publicado: (2019)

Capecitabine in the management of colorectal cancer
por: Hirsch, Bradford R, et al.
Publicado: (2011)

Capecitabine-Induced Coronary Vasospasm
por: Henry, Danish, et al.
Publicado: (2016)

Capecitabine-induced terminal ileitis
por: Al-Gahmi, Aboelkhair Mohammad, et al.
Publicado: (2012)

Capecitabine for primary breast cancer
por: Toi, Masakazu, et al.
Publicado: (2017)

Capecitabine-Associated Terminal Ileitis
por: van Hellemond, Irene E.G., et al.
Publicado: (2018)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine
por: Cohen, Philip R
Publicado: (2017)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer
por: Lu, Zhihao, et al.
Publicado: (2018)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan
por: Lee, Sung Uk, et al.
Publicado: (2013)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer
por: Chun, Brie, et al.
Publicado: (2022)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

HAND-FOOT SYNDROME DUE TO CAPECITABINE
por: Surjushe, Amar, et al.
Publicado: (2009)

Severe hypertriglyceridaemia during treatment with capecitabine
por: Javot, L, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_co155ani42d04uddf4isjjmjv5